PER-044-99未知未知
DOUBLE-BLIND, ONE YEAR PARALLEL GROUPS STUDY CONTROLLED WITH ACTIVE COMPARATOR AND CARRIED OUT IN BLIND CONDITIONS TO EVALUATE THE SAFETY AND EFFICACY OF MK-966 (L-748, 731) IN PURCHASE WITH SODIUM DICLOFENACO IN PATIENTS WITH KNEE AND HIP OSTEOARTHRITIS
MERCK SHARP & DOHME PERÚ S.R.L.,0 个研究点目标入组 0 人开始时间: 1999年2月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Patient completed Protocol 034-10 per-protocol through Visit 19.0 (Treatment Week 104).
- •Patient tolerated Protocol 034-10 study medication, and, in the opinion of the investigator and clinical monitor, demonstrated compliance with study procedures and study medication.
- •Patient understands the study procedures and agrees to participate in the study by signing the informed consent document.
- •Female patients of childbearing potential must demonstrate a urine (3-hCG level consistent with a nongravid state at Visit 19.0/21.0 and agree to remain abstinent or use oral contraceptives or use double-barrier contraception (partner using condom and patient using diaphragm, contraceptive sponge, or lUD) throughout the study and continuing at least 14 days after completion of treatment with study medication.
排除标准
- •Patient experienced and/or was withdrawn from the study because of serious or clinically important adverse experiences during Protocol 034-10 as determined by the investigator.
研究者
相似试验
进行中（未招募）
1 期
A study to compare how safe and effective OMS210 with placebo is for the treatment of Irritable Bowel SyndromeDiarrhoea predominant irritable bowel syndromeMedDRA version: 14.0Level: LLTClassification code 10048571Term: Irritable bowel syndrome aggravatedSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-019343-20-BEOTUS PHARMA CO., LTD.228
进行中（未招募）
不适用
A study to compare how safe and effective OMS210 with placebo is for the treatment of Irritable Bowel SyndromeDiarrhoea predominant irritable bowel syndromeMedDRA version: 14.1Level: LLTClassification code 10048571Term: Irritable bowel syndrome aggravatedSystem Organ Class: 100000004856EUCTR2010-019343-20-GBOTUS PHARMA CO., LTD.228
进行中（未招募）
不适用
A study to compare how safe and effective OMS210 with placebo is for the treatment of Irritable Bowel SyndromeDiarrhoea predominant irritable bowel syndromeMedDRA version: 14.1Level: LLTClassification code 10048571Term: Irritable bowel syndrome aggravatedSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-019343-20-DEOTUS Pharma CO., LTD.228
进行中（未招募）
不适用
A DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF OMS210 WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL SYNDROMEDiarrhoea predominant irritable bowel syndromeMedDRA version: 12.1Level: LLTClassification code 10048571Term: Irritable bowel syndrome aggravatedEUCTR2010-019343-20-HUOTUS PHARMACEUTICAL CO., LTD.417
进行中（未招募）
不适用
A DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF OMS210 WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL SYNDROMEEUCTR2010-019343-20-CZOTUS PHARMACEUTICAL CO., LTD.228